Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Laura S. Graham"'
Autor:
Laura S. Graham, Michael C. Haffner, Erolcan Sayar, Agnes Gawne, Michael T. Schweizer, Colin C. Pritchard, Ilsa Coleman, Peter S. Nelson, Evan Y. Yu
Publikováno v:
The Prostate. 83:641-648
Autor:
Laura S Graham, Bruce Montgomery, Heather H Cheng, Evan Y Yu, Peter S Nelson, Colin Pritchard, Stephanie Erickson, Ajjai Alva, Michael T Schweizer
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0233260 (2020)
BACKGROUND:While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in mismatch repair (MMR) genes (i.e. MMR deficiency; MMRd) or microsatellite
Externí odkaz:
https://doaj.org/article/72aa76cc3eb9475eb65eaa44e2277623
Autor:
Laura S. Graham, John K. Lin, Daniel E. Lage, Elizabeth R. Kessler, Ravi B. Parikh, Alicia K. Morgans
Publikováno v:
American Society of Clinical Oncology Educational Book.
The majority of men with prostate cancer are diagnosed when they are older than 65 years; however, clinical trial participants are disproportionately younger and more fit than the real-world population treated in typical clinical practices. It is, th
Publikováno v:
Cancers. 15:2552
Prostate cancer (PC) is the second leading cause of cancer death in men in the United States. While diversified and improved treatment options for aggressive PC have improved patient outcomes, metastatic castration-resistant prostate cancer (mCRPC) r
Publikováno v:
Cancer Invest
Gender parity within academic oncology is important. We hypothesized that gender differences exist in subspecialty choice and academic rank among medical oncologists. We performed a cross-sectional study of adult medical oncologists at the top 15 can
Autor:
Laura S. Graham, Michael T. Schweizer
Publikováno v:
The ProstateREFERENCES. 82
Despite recent therapeutic advances, castration-resistant prostate cancer (CRPC) remains a lethal disease and novel therapies are needed. Precision oncology provides an avenue for developing effective tailored approaches for treating malignancies bas
Publikováno v:
Clin Cancer Res
Mutational burden is positively correlated with tumor neoantigen load and studies have demonstrated an association between high tumor mutational burden (TMB) and response to checkpoint blockade. On the basis of a phase II study, the anti-PD-1 therapy
Publikováno v:
Urology. 136:e42-e44
Autor:
Laura S. Graham, George R. Schade, Petros Grivas, Jonathan L. Wright, Daniel W. Lin, Wen-Min Hou, Lawrence D. True, Peter S. Nelson, Todd Yezefski, Katie Nega, Nima Sharifi, Michael T. Schweizer, Nicholas P. Reder, Evan Y. Yu, Roman Gulati, Alvin A Matsumoto, Bruce Montgomery, Brett T. Marck, Katerina Alexander, William J. Ellis, Elahe A. Mostaghel
Publikováno v:
Prostate
Background Localized prostate cancers (PCs) may resist neoadjuvant androgen receptor (AR)-targeted therapies as a result of persistent intraprostatic androgens arising through upregulation of steroidogenic enzymes. Therefore, we sought to evaluate cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::329a963164137ffb64e3f658349c0b2a
https://europepmc.org/articles/PMC8044035/
https://europepmc.org/articles/PMC8044035/
Autor:
Alicia Ali, Scott T. Tagawa, Frank C. Cackowski, Vaibhav G. Patel, Divya Natesan, Clara Hwang, Michael Pierro, Ajjai Alva, Joseph J. Park, Tanya B. Dorff, Bicky Thapa, Susan Halabi, Colin Pritchard, Michael T. Schweizer, Rohan Garje, Abhishek Tripathi, Rana R. McKay, Albert Jang, Marcin Cieslik, Catherine Handy Marshall, Laura S Graham, Justin Shaya, Tomi Jun, Landon Carter Brown, Alleda Mack, Elisabeth I. Heath, Vadim S. Koshkin, Christopher Nguyen, Pedro C. Barata, Olesia Kellezi, Deepak Kilari, Mehmet Asim Bilen, Sanober Nusrat, Luna Acharya, Deepak Ravindranathan, Matthew Labriola, Andrew J. Armstrong, William Oh, Shuang R. Chen, Angelo Cabal, Amanda Pilling
Publikováno v:
Prostate cancer and prostatic diseases. 25(3)
Purpose Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A “real-world” clinical-genomic database is urgently ne